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Abstract
Deregulation of the non-receptor tyrosine kinase ETK/BMX has been reported in several solid tumors. In this report, we
demonstrated that ETK expression is progressively increased during bladder cancer progression. We found that down-
regulation of ETK in bladder cancer cells attenuated STAT3 and AKT activity whereas exogenous overexpression of ETK had
opposite effects, suggesting that deregulation of ETK may attribute to the elevated activity of STAT3 and AKT frequently
detected in bladder cancer. The survival, migration and invasion of bladder cancer cells were significantly compromised
when ETK expression was knocked down by a specific shRNA. In addition, we showed that ETK localizes to mitochondria in
bladder cancer cells through interacting with Bcl-XL and regulating ROS production and drug sensitivity. Therefore, ETK may
play an important role in regulating survival, migration and invasion by modulating multiple signaling pathways in bladder
cancer cells. Immunohistochemistry analysis on tissue microarrays containing 619 human bladder tissue samples shows that
ETK is significantly upregulated during bladder cancer development and progression and ETK expression level predicts the
survival rate of patients with cystectomy. Taken together, our results suggest that ETK may potentially serve as a new drug
target for bladder cancer treatment as well as a biomarker which could be used to identify patients with higher mortality
risk, who may be benefited from therapeutics targeting ETK activity.
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Introduction
Bladder cancer is one of the most common cancers in the
United States. It is estimated that there will be 70,530 new cases
and 14,680 deaths due to bladder cancer in 2010 [1,2,3]. Multiple
genetic and epigenetic factors are believed to contribute to the risk
of developing bladder cancer. In addition to well known risk
factors such as aging, gender, exposure to cigarette smoke and
industrial chemicals, several genetic lesions that provide cues for
cell transformation, proliferation, migration and invasion in
bladder cancer have been identified [4]. These include mutations
or alterations in expression of p53, pRb, E-cadherin, COX2,
BLCA-4, CXCL1, MMP-2/9 and EGFR [5]. Cumulative
increase in these genetic defects also provides prognostic
assessment for disease outcome. However, further understanding
of bladder tumor biology is necessary to develop more effective
therapy. There is thus a need for the identification and application
of novel therapeutic targets in bladder cancer.
Epithelial and endothelial tyrosine kinase (ETK), also known as
Bone Marrow X kinase (BMX), is a member of Tec family non-
receptor tyrosine kinase. ETK contains an NH2-terminal
Pleckstrin homology domain, a Src homology 3 domain, a Src
homology 2 domain, and a COOH-terminal tyrosine kinase
domain [6]. ETK can be activated by several extracellular stimuli,
including growth factors, cytokines, extracellular matrix and
hormones [7]. ETK protein is present in cytoplasm with strong
perinuclear staining in cells when examined using immunofluo-
rescence microscopy [8,9,10]. Activation of ETK kinase activity
can be achieved by interaction of its pleckstrin homology domain
either with the phosphatidylinositol 3-kinase product phosphati-
dylinositol 3,4,5-triphosphate or the FERM domain of FAK,
which leads to plasma membrane translocation of ETK [6,8].
ETK has been shown to play a role in various cellular processes
including cell proliferation, transformation, differentiation, migra-
tion and metastasis. ETK can interact with FAK and p130
Cas to
regulate actin cytoskeleton and cell motility [8,11]. It has also been
shown that ETK directly interacts with tumor suppress p53 and
inhibit its nuclear translocation, thereby promoting chemoresis-
tance in cancer cells [9]. We previously showed that ETK is
progressively upregulated during human prostate cancer develop-
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bladder cancer cells remains unknown.
In this report, we demonstrated that ETK expression is
progressively increased during bladder cancer progression. ETK
plays an important role in regulating survival, migration and
invasion by modulating multiple signaling pathways in bladder
cancer cells. We further showed that ETK is also located in
mitochondria through directly interacting with Bcl-XL and
regulating ROS production in response to treatment of chemo-
therapeutic drugs. Furthermore, ETK expression positively
correlates tumor grade and predicts patient outcome. Our data
suggest that ETK may potentially serve as a drug target and
prognostic marker for bladder cancer.
Results
Functional Etk is overexpressed in bladder cancer
We examined ETK expression in a panel of human bladder
cancer cell lines and found that ETK expression level was varied in
these cells. Interestingly, a significantly higher level of ETK
protein was detected in UM-UC-3 and T24 cells which are
derived from high-grade and invasive bladder tumors (Fig. 1A).
We then examined whether ETK is functional in these invasive
cells. We first tested whether growth factor could activate ETK
kinase activity using phosphorylation of tyrosine 40 (Y40), an
autophosphorylation site by ETK upon its activation [8], as
readout. As shown in Fig. 1B, EGF treatment induced Y40
phosphorylation, suggesting that ETK is active in bladder cancer
cells. Consistent with previous studies showed that ETK is
upstream of STAT3 and AKT pathways [15,16], we found the
phosphorylation level of both STAT3 and AKT was compromised
when ETK expression was knocked down by a specific shRNA
(Fig. 1C, Left). Conversely, when we overexpressed ETK in 5637
cells with a relatively lower level of endogenous ETK, we detected
an increased activity of both STAT3 and AKT (Fig. 1C, Right).
These data together indicated that ETK is highly expressed in
invasive bladder cancer cell lines and involved in regulating
STAT3 and AKT activity.
Etk is present in mitochondria and associated with Bcl-XL
When we examined cellular localization of ETK in bladder
cancer cells, we observed a puncate distribution of ETK in the
cytoplasm. Interestingly, ETK staining was partially overlapped
with Mitotracker labeling in these cells (Fig. 2A). We also detected a
significant amount of ETK protein in the mitochondrial fraction,
along with other known mitochondrial proteins Bcl-XL and VDAC
(Fig. 2B). As ETK lacks a mitochondria targeting signal, we
wondered whether it could localize to mitochondria through a
protein-protein interaction. As shown in Fig. 2C, endogenous Bcl-
XL was co-precipitated with ETK in both bladder cancer cell lines
examined. Similar results were also obtained in 293T cells
overexpressing both T7-tagged ETK and GFP-tagged Bcl-XL.
These data suggested that ETK may form a complex with Bcl-XL
and localize to mitochondria. Due to Bcl-XL’s anti-apoptotic
function, we examined the role of ETK in regulating apoptosis in
these cells. As shown in Fig. 3A, knock-down of ETK expression by
a specific shRNA significantly increased the number of apoptotic
cells in UM-UC-3 and T24 cells. In addition, inhibition of ETK
activity enhanced ROS production and cytotoxicity in bladder
cancer cells in response to treatment of Doxorubucin, while
overexpression of ETK had protective effects (Fig. 3B & 3C).
Tumor growth and metastasis is regulated in part by the ability of
tumor cells to degrade surrounding matrix tissue and migrate. To
test whether ETK upregulation may cause such a phenotype, we
further examined the effects of ETK knock-down on bladder cancer
cell migration and invasion using the Boyden chamber assays.
Fig. 3D shows that migration of ETK-knockdown UM-UC-3 and
T24 cells was reduced to 40% and 60% respectively compared with
the control shRNA treated cells. Similar results were also observed
when we examined their ability to invade through matrigel. These
data suggested that inhibition of ETK expression in bladder cancer
cells compromised both migration and invasion.
Etk is upregulated in human bladder cancer tissue and
predicted patient survival
To examine ETK expression in human bladder tumor tissues,
we performed immunohistochemistry analysis on human bladder
Figure 1. Functional Etk is expressed in bladder cancer cell lines. A, Expression profile of ETK in bladder cancer cell lines. ETK expression level
in total cell lysates from bladder cancer cell lines was examined by immunoblotting with anti-ETK. Tubulin was used as a loading control. B, Activation
of ETK in bladder cancer cells treated with EGF. UM-UC-3 and T24 cells were serum starved for 24 h, then treated with 20 ng/ml EGF for 15 or 30 min.
The level of activated EGFR and ETK was monitored by immunoblotting with anti-pEGFR(Y1175) and anti-pETK(Y40) respectively. The level of total
EGFR and ETK in the cell lysates was also detected with anti-EGFR and anti-ETK respectively. C, Regulation of STAT3 and AKT activity by ETK in bladder
cancer cells. UM-UC-3 and T24 cells were infected with lentivirus encoding the shRNA specific for ETK or a vector control. At 24 h post-infection, cells
were serum starved overnight and then lysed. The level of active STAT3 and AKT was examined by immunoblotting with anti-pSTAT3 (Y705) and anti-
pAKT (S473) respectively (Left panel). The effect of ETK overexpression on STAT3 and AKT activity was also examined in bladder cancer 5637 cells
(Right panel).
doi:10.1371/journal.pone.0017778.g001
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patients. ETK staining appeared to be both cytoplasmic and
nuclear positive (Fig. 4A), and ETK expression was markedly
increased in bladder tumor tissues compared to their benign
counterparts (Table 1). In addition, ETK expression level was
significantly higher in invasive T1-T4 tumors than that in non-
invasive Tis/Ta counterparts (p,0.001); however, ETK expres-
sion did not differ significantly within T1 to T4 tumors (data not
shown). In addition, ETK expression increased with tumor grade
(p,0.001). ETK expression in CIS was a notable exception, with a
mean 12% in cytoplasm, which is lower than G1–G3 scores
(Table 1), suggesting an association of ETK overepression with
bladder papillary tumors. To assess whether ETK could be used as
a potential prognostic marker, clinical outcome analysis was
performed on 118 patients underwent cystectomy who were
followed up for a median of 92.3 months. We identified a cutoff
point of 15% for optimal substratification of these patients
according to ETK cytoplasmic expression. There were 75 tumors
(64%) with low expression (#15%) and 43 tumors (36%) with high
expression (.15%). Kaplan-Meier analysis indicated that patients
who had higher cytoplasmic staining of ETK (staining score
.15%) had poorer overall survival probability (Fig. 4B, log-rank
test p=0.0028). Furthermore, multivariable Cox Regression
Analysis showed that ETK is a significant predictor of survival
after adjusting for other important clinicopathological variables
including age, tumor grade, stage and positive lymph node status
(Table 2). As indicated in the model, ETK was the only
independent prognostic predictor for overall survival with hazard
ratio of 1.7 (95% CI: 1.1 to 2.7, p=0.0159). Taken together, these
data showed that ETK expression is increased in bladder cancer
and associated with tumor progression and poor prognosis.
Discussion
Overexpression of ETK has been reported in several cancers,
including prostate, breast and lung cancers [8,13,17,18]. This is
the first report on deregulation of ETK expression in bladder
cancer. Frequently elevated ETK expression in bladder cancer
cells suggested that ETK may play a causal role in disease
development and progression. This was supported by our
Figure 2. ETK localizes to mitochondria and interacts with Bcl-XL in bladder cancer cells. A, ETK localizes to mitochondria in UM-UC-3 and
T24 cells. Cells were labeled with Rhodamine Mitotracker, followed by immunofluorescence staining with anti-ETK. Nuclei were counterstained using
DAPI. Localization of ETK was determined by confocal microscopy. Yellow shows colocalization of ETK and Mitotracker. B, ETK protein is detected in
mitochondrial fraction. Mitochondrial and cytosolic fractions were prepared as described in Methods. The fractionated extracts were subjected to
immunoblotting with anti-ETK or indicated antibodies for fractionation markers. ERK was used as a cytosolic marker, while Bcl-XL and VDAC as
mitochondrial markers. C, ETK is associated with Bcl-XL. Total cell extracts from UM-UC-3 and T24 cells were immunoprecipitated with anti-ETK or IgG
control, followed by immunoblotting with the antibodies as indicated (Left panel). 293T cells were co-transfected with T7-Etk and GFP-Bcl-XL,
immunoprecipitation was performed using anti-T7 (Center panel) or anti-GFP (Right panel), followed by immunoblotting with the antibodies as
indicated.
doi:10.1371/journal.pone.0017778.g002
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PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17778Figure 3. Regulation of survival, migration and invasion by ETK in bladder cancer cells. A, Down-regulation of ETK expression induced
apoptosis in bladder cancer cells. UM-UC-3 and T24 cells were infected with lentivirus encoding the specific shRNA for ETK for 96 h and apoptosis was
evaluated by TUNEL assays. Apoptotic cells were quantified by counting TUNEL-positive cells from five random independent fields. B, ETK regulates
ROS activity and cytotoxicity in bladder cancer cells in response to Doxorubucin (DOX) treatment. Cells were infected with lentivirus encoding the
shRNA specific for ETK, Etk T7-tagged ETK or a vector control. At 48 h postinfection, cells were treated with DOX (UM-UC-3, 0.5 mg/ml; T24 cells,
2.5 mg/ml) for 20 h and then incubated with 10 nM 5(6)-CDCFDA for 30 min. ROS-positive cells were counted under the fluorescence microscopy.
The results were expressed as percentage of the control. C, ETK regulates cytotoxicity in bladder cancer cells in response to DOX treatment. Cells
were infected as described in B and treated with DOX (T24, 5 mg/ml; UM-UC-3, 0.5 mg/ml) for 48 h. Cell viability was assessed by WST-1 assays (Top
panel). The level of ETK expression was monitored by immunoblotting with anti-ETK (Bottom panel). *, p,0.05 compared with the control; **, p,0.01
compared with the control. D, Knockdown of ETK inhibited migration and invasion in vitro. Cell migration and invasion assay were described as
Methods. The results were expressed as percentage of the control. *, p,0.05 compared with the control; **, p,0.01 compared with the control.
doi:10.1371/journal.pone.0017778.g003
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was previously demonstrated to induce growth and enhance
invasion of bladder cancer cells by regulating of AKT activity
[19,20]. The EGF receptor has been reported highly expressed in
bladder cancer cells and is associated with cancer progression and
poor prognosis in patients [21,22,23]. Therefore, ETK may likely
act as a downstream effector of EGF/EGFR to promote bladder
tumor growth and metastasis. It has been shown that ETK
overexpression can increase proliferation in mouse prostate
epithelium and result in development of prostatic intraepithelial
neoplasia (PIN) partly by increasing AKT and STAT3 activity
[13]. We found that down-regulation of ETK in bladder cancer
cells attenuated STAT3 and AKT activity whereas exogenous
overexpression of ETK had opposite effects. Deregulation of
STAT3 and PI3K/AKT pathways has been shown to play an
important role in the development of urothelial carcinoma and
correlates with tumor progression [24,25]. It is possible that ETK
may exert its role in bladder cancer through regulating these
Figure 4. A, The representative fields of human bladder cancer TMAs stained with anti-ETK antibody. B, Kaplan-Meier analysis on association of ETK
cytoplasmic staining with the survival rate of patients with cystectomy.
doi:10.1371/journal.pone.0017778.g004
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cells to invade normal tissues. We showed that bladder cancer cells
could effectively invade a matrix barrier in vitro, and this ability
was markedly dismissed when ETK expression was knocked down
by a specific shRNA. Knockdown ETK leads to diminished
activation of STAT3, which plays a role in bladder cancer
invasion, partially explained the possible mechanism of invasion
inhibition. The effect of ETK on cell migration could be explained
based on the established role of ETK in cell migration in prostate
and breast cancer cells through FAK-mediated integrin signaling
[8].
In addition to STAT3 and AKT pathways which are known to
be activated by ETK, we also showed, for the first time, that ETK
localizes to mitochondria in bladder cancer cells and thereby
regulates ROS production and drug sensitivity. Other tyrosine
kinases, including Src and EGFR, have been shown to be present
in mitochondria. Salvi et al reported that Src is located in
mitochondria in rat brain [26]. EGFR and Src can translocate to
mitochondria by binding the subunit k of mitochondrial
cytochrome coxidase (Coxa) in an EGF dependent manner and
modulate mitochondrial function through phosphorylating Coxa
[27]. However the exact function of ETK in mitochondria has yet
to be established. We found that ETK is associated with a Bcl-2
family member Bcl-XL in bladder cancer cells. Knockdown of
ETK expression leads to an increase of ROS production and
sensitization of bladder caner cell to chemotherapeutic drugs. It
has been shown that DNA damage, irradiation and hypoxia can
induce ROS in cancer cells [28,29]. We previously showed that
ETK can confer drug resistance in prostate cancer cells by
interacting with p53 and inhibiting its nuclear transduction
function. It is possible that ETK may also promote drug resistance
through its protective effect on mitochondrial function. Our results
therefore demonstrated that ETK affords a malignant and invasive
phenotype to bladder cancer cells through regulating multiple
signaling pathways (Fig. 5).
It has been shown that STAT3 activity and expression is
increased in bladder cancer tumor and predicts tumor recurrence
and patient survival [30,31]. Our IHC analysis on bladder cancer
TMAs showed that ETK expression is increased in bladder cancer
tissues compared with their benign counterparts. Considering that
targeted expression of ETK in mouse prostate leads to the
development of PIN [13], it is possible that ETK may also play a
role in oncogenic transformation in bladder urothelial cells. More
importantly, ETK expression is higher in invasive (T1–T4) than
non-invasive bladder tumors (Tis/Ta), suggesting that ETK may
also play a role in tumor invasion and metastasis. This possibility
was supported by our observation that knockdown of ETK
expression in bladder cancer cells inhibit their activity in in vitro
invasion assays. Furthermore, we found that ETK expression level
also can predict survival of patients with cystectomy treatment
independent of other important clinicopathological variables
including age, tumor grade, stage and positive lymph node status.
Therefore, ETK may potentially serve as a new drug target for
bladder cancer treatment as well as a biomarker which could be
used to stratify patients with higher mortality risk. These patients
may be beneficial from therapeutics targeting ETK activity.
Materials and Methods
Cell Culture, transfection and lentiviral infection
Human bladder cancer cell line T24, 5637, J82, RT-4 and UM-
UC-3 as well as 293T were purchased from American Type
Culture Collection (ATCC). UM-UC-3, T24 and 293T cells were
grown in Dulbecco’s modified Eagle’s medium. 5637, J82 and RT-
4 cells were maintained in RPMI 1640 with 10% fetal bovine
serum and 1% (v/v) penicillin and streptomycin (100 mg/ml) and
maintained at 37uC in a 5% CO2 atmosphere. Cells were
transfected with HD FuGENE 6 (Roche Molecular Biochemicals)
following the manufacturer’s instruction. Lentivirus infection was
carried out as previously [9].
Immunoprecipitation and Western Blot
Cells were lysed in the lysis buffer (20 mM Tris/HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
1m M N a 3VO4, 1 mg/ml aprotinin, 1 mg/ml leupeptin, and
1 mM phenylmethyl-sulfonyl fluoride). Insoluble material was
removed by centrifugation, and antibodies were added to lysate for
overnight at 4uC. Antibodies were collected using protein A or
protein G-Sepharose beads, and protein complexes were washed
three times at 4uC with the lysis buffer. Immunoblotting was done
Table 1. ETK cytoplasmic expression in bladder tissue.
Group Mean ± SE N(%)
Grade
Normal 12.6660.74 193 (32.60)
G1 24.4261.82 26 (4.39)
G2 25.1861.26 125 (21.12)
G3 25.5560.91 176 (29.73)
CIS 12.1761.05 72 (12.16)
p Value ,0.0001
Stage
Normal 12.6660.73 193 (31.2)
Non-invasive(Tis,Ta) 20.4960.99 187 (30.2)
Invasive(T1–T4) 25.0660.82 239 (38.6)
p Value ,0.0001
doi:10.1371/journal.pone.0017778.t001
Table 2. Multivariate Cox regression analysis on survival in
patients with Cystectomy.
Covariate HR (95% CI) p Value
Age$70 yr 1.512 (0.968–2.361) 0.0692
Grade 3 vs 1–2 1.264 (0.635–2.514) 0.5045
Stage T1-4 vs Tis/Ta 1.167 (0.480–2.837) 0.7325
N+ vs N0 1.650 (0.934–2.913) 0.0845
Etk Cytoplasmic (.15) 1.732 (1.108–2.706) 0.0159
doi:10.1371/journal.pone.0017778.t002
Figure 5. Postulated role of ETK in bladder cancer.
doi:10.1371/journal.pone.0017778.g005
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were resolved on a SDS polyacrylamide gel and transferred to a
polyvinylidene difluoride membrane. Blots were incubated with
the indicated primary antibodies overnight at 4uC and followed by
detection with horseradish peroxidase-conjugated secondary
antibody. The monoclonal anti-BMX antibody (BD Transduction
Laboratories) was used at 1:2000, whereas anti-pSTAT3(Y705),
AKT, pAKT(S473), EGFR, pEGFR(Y1175) and pETK(Y40)
(Cell Signaling Technology, Danvers, MA) were used at 1:1,000.
Anti-Bcl-XL, anti-tubulin, ERK, VDAC and anti-signal transduc-
ers and activators of transcription 3(STAT3) (Santa Cruz
Biotechnology, Santa Cruz, CA) were used at 1:2,000.
WST-1, colony formation and TUNEL assays
Cells were seeded in 96-well plates at a density of 1610
3 cell/
well and infected with the lentivirus encoding the ETK shRNA or
a control shRNA. At each indicated time point, cell viability was
measured by WST-1 (Roche) assay following the manufacturer’s
protocol. For colony formation assay, cells (1610
4) were seeded in
6-well plates and infected with the lentivirus for control shRNA or
ETK shRNA. Cell culture was maintained in complete medium
for 14 days. Cell colonies were then visualized by Coomassie blue
staining. UM-UC-3 and T24 cells were infected with the lentivirus
encoding ETK shRNA or a control for 96 h and apoptotic cells
were detected by TUNEL assay following the manufacturer’s
instructions (Roche). Apoptotic cells were quantified by counting
TUNEL-positive cells from five random independent fields.
Cell migration and invasion assays
Cell migration was assessed by transwell assay as described
previously [8]. Briefly, infected cells were harvested, resuspended
in serum-free medium, and then transferred to the top chambers
(5610
4 cells per well) while the bottom chambers containing
0.5 ml of Conditioned medium from NIH 3T3 fibroblasts. After
24 h incubation, cells on the upper surface were scraped and
washed away, whereas the cells migrated to the lower surface were
fixed and stained with 49,6-diamidino- 2-phenylindole (DAPI) for
5 min and then counted under a fluorescence microscope, and the
relative number to the vector control was calculated. Cell invasion
assay was performed in conditions similarly as above, except for
the transwell filters were pre-coated with Matrigel (BD Bioscienc-
es) and 1610
5 cells were used per well.
Immunofluorescence and confocal microscopy analysis
Cells were labeled in fresh culture media with 200 nM
Mitotracker (Invitrogen) at 37uC for 30 min, and were then fixed
with 3.75% formalin for 15 min followed by incubation with
blocking solution [10% donkey serum 0.5% bovine serum
albumin, 0.3% triton X-100 in PBS] and treated with ETK
antibody for overnight at 4uC. The immunoreactions were
revealed by incubation of the cells with goat anti-mouse FITC
488–conjugated IgG (Jackson Immuno Research) and DAPI
(1:5000) for 5 min. Finally, the coverslip containing the immuno-
labeled cells were mounted with an anti-fading mounting medium
(Biomeda gel mount, Electron Microscopy Sciences). The cells
were evaluated using a water immersion 40X objective lens of a
Zeiss 510 confocal microscope equipped with 347-, 488-, and 543-
nm laser beams.
Mitochondrial preparation and Reactive Oxygen Species
(ROS) detection
Mitochondria fraction was purified with Mitochondria Isolation
Kit for Cultured Cells (PIERCE) according to the manufacturer’s
instructions. Intracellular ROS was measured by using the dye
5(6)-CDCFDA (molecular probes). After passing through the
plasma membrane, this lipophilic and no-fluorescent compound is
deesterified to a hydrophilic alcohol (H2DCF) that may be
oxidized to fluorescent DCF by a process usually considered to
involve with ROS. Cultured cells were loaded with 10 mM 5(6)-
CDCFDA in normal medium at 37uC for 30 min. After
incubation, cells were washed three times with medium and left
the last washing medium for imaging studies. Imaging was taken
by fluorescence microscope using a Nikon TE2000s inverted
microscope with 10x objective.
Tissue microarray, Immunohistochemistry and Statistical
analysis
Tissue microarrays (TMAs) were prepared by the department of
Pathology at the University of California, Los Angeles (UCLA)
Medical Center as previously described [14]. Investigators were
only provided with clinical-pathological data such as the tumor
stage and grade. All patient identifiers were removed so that it is
not possible to trace any tissue to a particular patient. Therefore,
patient confidentiality is protected. Under the protocol approved
by the IRB committee at UCLA, no patient consent is required for
this study. TMA were deparaffinized with xylene and stained as
previously described [13]. Briefly, slides were rehydrated and
antigen retrieval was achieved by microwave for 15 min in citrate
buffer. Slides were then incubated in 0.3% hydrogen peroxide to
quench endogenous horseradish peroxidase (HRP) for 30 min.
Slides were preincubated with normal goat serum in PBS (1:20) for
60 min at room temperature. Slides were then incubated with
primary antibody ETK (1:2000) at 4 degree overnight. Subse-
quently, slides were incubated with biotin-labeled anti-rabbit IgG
and incubated with preformed avidin-biotin peroxidase complex.
Finally, the slides were counterstained with hematoxylin, dehy-
drated and mounted.
Slides were analyzed using the Ariol SL-50 automated slide
scanner (Applied Imaging, San Jose, Calif) to quantitate the
amount of positive staining for each area of interest. Thresholds
for each image were applied using the Ariol analytical software
based on multiple parameters: RGB algorithm, shape and size. All
analyses were performed with the MultiStain script. Thresholded
classifiers were customized for each stain.
For assessing nuclear staining, positive DAB staining was
calculated by applying two color thresholds with one recognizing
blue background (haematoxylin stained) cells and another
recognizing brown positive cells and blue, non-positive cells (total
cell number). Individual cells were discriminated by incorporating
the shape and size thresholds, providing, together with the color
thresholds, actual cell counts. Percent of positivity was determined
by dividing the cell number detected by the brown threshold by
the total cell number, detected by the sum of the brown and blue
thresholds. Total tissue area analyzed was also included in the final
analysis (mm
2).
For assessing cytoplasmic staining, the area positive stain was
calculated by applying color thresholds to detect positive brown
pixels. Percent of positivity was determined by dividing the total
positive stain area (mm
2) by the total tissue area analyzed (mm
2).
The immunoreactive score for each case was quantified by the
average of four cores. Associations between ETK expression and
pathological parameters were assessed with the nonparametric
Kruskal-Wallis tests. Different survival/recurrence endpoints were
assessed for patients who underwent TUR and patients who
underwent cystectomy. Kaplan–Meier curves were used to
estimate survival/recurrence-free time curves and the log rank
test was used to test whether the curves differed between groups.
ETK Predicts Poor Prognosis in Bladder Cancer
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17778COX multiple proportional hazards model was used to assess
which covariates affect survival/recurrence-free time. For each
covariate, the relative hazard rate and the associated P value were
reported. All analyses were performed with the software SAS
version 9.2.
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